Candel Therapeutics' CAN-2409 extended survival in NSCLC patients, with biomarker data showing enhanced response in ...

Candel Therapeutics, Inc. (NASDAQ: CADL) shares are are trading lower Thursday after the company released final survival data from its phase 2a clinical trial of CAN-2409.

We recently published a list of 10 Hot Biotech Stocks Under $5. In this article, we are going to take a look at where Compass ...

PD-1, PD-L1, and VEGF inhibitors have been approved for over 50 indications in addition to NSCLC. Summit CEO Maky Zanganeh ...

The explosion of GLP-1 weight loss drugs is reminiscent of the early days of PD-1 inhibitors, but key market differences ...

Checkpoint inhibitors such as tislelizumab have improved ... the Company is taking a major step towards realizing the full potential of its Decoy platform. About Indaptus Therapeutics Indaptus ...

A new precision oncology paper was published in Oncotarget, Volume 16, on March 12, 2025, titled “Worldwide Innovative ...

Takeda is sharpening its oncology focus amid an R&D revamp. Sun Pharma will acquire Checkpoint Therapeutics and an ...

Sun Pharmaceutical Industries Ltd’s latest acquisition of US-based Checkpoint Therapeutics, Inc. is good news for its speciality business–an area of focus. Checkpoint is an immunotherapy and ...

Checkpoint Therapeutics (NASDAQ:CKPT – Get Free Report)‘s stock had its “neutral” rating reissued by research analysts at HC Wainwright in a research note issued to investors on Tuesday, Ratings ...

Checkpoint Therapeutics (NASDAQ:CKPT – Get Free Report)‘s stock had its “hold” rating reiterated by equities research analysts at Lake Street Capital in a research report issued on Monday ...